Immunogenicity of rVSVΔG-ZEBOV-GP Ebola vaccine (ERVEBO®) in African clinical trial participants by age, sex, and baseline GP-ELISA titer: A post hoc analysis of three Phase 2/3 trials-Reference-Cited by-同舟云学术

Immunogenicity of rVSVΔG-ZEBOV-GP Ebola vaccine (ERVEBO®) in African clinical trial participants by age, sex, and baseline GP-ELISA titer: A post hoc analysis of three Phase 2/3 trials

Published:2022-11 Issue:46 Volume:40 Page:6599-6606
ISSN:0264-410X
Container-title:Vaccine
language:en
Short-container-title:Vaccine

Author:

Simon Jakub K.,Kennedy Stephen B.,Mahon Barbara E.,Dubey Sheri A.,Grant-Klein Rebecca J.,Liu Ken,Hartzel Jonathan,Coller Beth-Ann G.,Welebob Carolee,Hanson Mary E.,Grais Rebecca F.

Publisher

Elsevier BV

Subject

Infectious Diseases,Public Health, Environmental and Occupational Health,General Veterinary,General Immunology and Microbiology,Molecular Medicine

Reference39 articles.

1. WHO. Ebola virus disease (2021), Accessed: 26 Aug 2022.

2. FDA. FDA Approves First Treatment for Ebola Virus (2020), Accessed: 26 Aug 2022.

3. FDA. FDA approves treatment for ebola virus (2020), Accessed: 26 Aug 2022.

4. CDC. Ebola (Ebola Virus Disease) Prevention and Vaccine (2021), Accessed: 26 Aug 2022

5. Ebola in DRC: Recommendations for accelerating outbreak control. 1-4 (WHO Scientific and Technical Advisory Group for Infectious Hazards (STAG-IH), 2019).

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Vaccine adjuvants for infectious disease in the clinic;Bioengineering & Translational Medicine;2024-03-22

2. Delving into revolutionary SARS-CoV-2 vaccine approaches: Molecular and virological examinations; principles of SARS-CoV-2 vaccine platform;Vacunas (English Edition);2024-01

3. Modeling Supply and Demand Dynamics of Vaccines against Epidemic-Prone Pathogens: Case Study of Ebola Virus Disease;Vaccines;2023-12-25

4. Immunogenicity and safety of ebolavirus vaccines in healthy adults: a systematic review and meta-analysis of randomized controlled trials;Expert Review of Vaccines;2023-12-22

5. Immunogenicity and Vaccine Shedding After 1 or 2 Doses of rVSVΔG-ZEBOV-GP Ebola Vaccine (ERVEBO®): Results From a Phase 2, Randomized, Placebo-controlled Trial in Children and Adults;Clinical Infectious Diseases;2023-11-15